← Teva Pharma Industries Ltd ADR overview

Teva Pharma Industries Ltd ADR vs Bristol-Myers Squibb: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Teva Pharma Industries Ltd ADR (TEVA)

Q3 2026
▲3

Teva Q3: Pipeline Expansion, Guidance Raise, Debt Cut, But Pricing Risks Loom

  • Pipeline Expansion and Strategic Deals Teva acquired BioXcel, gained FDA acceptance for an Entyvio biosimilar, advanced Phase 3 duvakitug, and signed a Samsung Bioepis biosimilar deal, broadening its pipeline and biosimilar portfolio.

    These moves expand Teva's future revenue sources and support its Pivot to Growth strategy.

  • Strong Sales Drive Guidance Raise Robust sales of AUSTEDO, AJOVY, and UZEDY led to a $75 million guidance raise and a Q2 revenue beat, showcasing the strength of Teva's branded drug portfolio.

    This directly reflects better-than-expected financial performance and improved outlook.

  • Debt Reduction and Listing Upgrade Teva completed a $4.9 billion refinancing, secured investment-grade ratings early, and replaced ADRs with a direct NYSE listing, strengthening its balance sheet and market presence.

    These actions improve financial flexibility and may attract a broader investor base.

  • Margin Targets vs. Pricing Pressures Management targets ~55% gross and 30% operating margins by 2027 with $700 million in cost savings, but Medicaid cuts and most-favored-nation pricing threaten revenue, and adjusted EPS missed estimates.

    This highlights the tension between ambitious profitability goals and external pricing challenges.

September 2026
▲4

Teva's Growth Pivot Accelerates with Pipeline, Cost Cuts, and New Deals

  • Teva's 'Pivot to Growth' Strategy Accelerates Teva said its growth strategy is accelerating, with debt cut, investment-grade ratings secured ahead of plan, and raised sales targets for key drugs like AUSTEDO and AJOVY. This boosts confidence in future revenue and earnings, supporting a higher stock price.

    This is a major update on Teva's strategic progress, directly impacting investor confidence and future growth prospects.

  • New Schizophrenia Data Supports Potential Blockbuster New Phase 3 data for TEV-'749, a long-acting schizophrenia treatment, showed high stabilization and low relapse rates. With an FDA decision expected soon, this could become a significant new product, driving future revenue and stock gains.

    This is new clinical data that de-risks a key pipeline asset and highlights near-term regulatory catalyst.

  • CEO Details Margin Expansion and Cost Savings Teva's CEO outlined a plan to expand gross margin to ~55% and achieve a 30% operating margin by 2027, backed by $700 million in cost savings. The innovative business grew 40% in Q2, showing the strategy is working and boosting profitability outlook.

    This provides concrete financial targets and evidence of margin improvement, key drivers for earnings and stock valuation.

  • Teva Expands Biosimilar Pipeline with Samsung Bioepis Deal Teva signed a global deal with Samsung Bioepis for up to six biosimilar candidates, adding to its pipeline. This expands Teva's biosimilar portfolio and commercial reach, supporting long-term growth in a high-margin area.

    This is a new partnership that strengthens Teva's biosimilar business, a key growth driver.

Latest
▲4

Teva's Growth Pivot Accelerates with Pipeline, Cost Cuts, and New Deals

  • Teva's 'Pivot to Growth' Strategy Accelerates Teva said its growth strategy is accelerating, with debt cut, investment-grade ratings secured ahead of plan, and raised sales targets for key drugs like AUSTEDO and AJOVY. This boosts confidence in future revenue and earnings, supporting a higher stock price.

    This is a major update on Teva's strategic progress, directly impacting investor confidence and future growth prospects.

  • New Schizophrenia Data Supports Potential Blockbuster New Phase 3 data for TEV-'749, a long-acting schizophrenia treatment, showed high stabilization and low relapse rates. With an FDA decision expected soon, this could become a significant new product, driving future revenue and stock gains.

    This is new clinical data that de-risks a key pipeline asset and highlights near-term regulatory catalyst.

  • CEO Details Margin Expansion and Cost Savings Teva's CEO outlined a plan to expand gross margin to ~55% and achieve a 30% operating margin by 2027, backed by $700 million in cost savings. The innovative business grew 40% in Q2, showing the strategy is working and boosting profitability outlook.

    This provides concrete financial targets and evidence of margin improvement, key drivers for earnings and stock valuation.

  • Teva Expands Biosimilar Pipeline with Samsung Bioepis Deal Teva signed a global deal with Samsung Bioepis for up to six biosimilar candidates, adding to its pipeline. This expands Teva's biosimilar portfolio and commercial reach, supporting long-term growth in a high-margin area.

    This is a new partnership that strengthens Teva's biosimilar business, a key growth driver.

August 2026
▲3▼1

Teva's pipeline and branded drugs shine despite pricing headwinds

  • Pipeline expansion and regulatory wins Teva agreed to acquire BioXcel's IGALMI and BXCL501, the FDA accepted a subcutaneous Entyvio biosimilar, and duvakitug entered Phase 3 with $2-5 billion peak sales potential. These moves strengthen Teva's pipeline and future growth prospects.

    These pipeline advancements are new and directly support Teva's long-term growth story.

  • Strong financial performance and guidance raise Teva raised 2026 revenue guidance by $75 million on AUSTEDO, AJOVY, and UZEDY strength, and Q2 sales beat at $4.1 billion. This shows the branded drug strategy is delivering results.

    The guidance increase and sales beat are new and highlight Teva's improving financial performance.

  • Balance sheet improvement and listing change Teva completed a $4.9 billion debt refinancing that lowered interest costs and replaced its ADRs with a direct NYSE listing. These actions reduce expenses and simplify trading for investors.

    These are new capital structure changes that benefit Teva's financial health and investor accessibility.

  • Pricing pressures and earnings miss Medicaid price cuts and most-favored-nation pricing may pressure revenue, and adjusted EPS missed estimates. The BioXcel deal initially pushed shares down 1%, reflecting investor concerns.

    These are new negative factors that could weigh on Teva's stock price.

▲4

Teva's Branded Drug Push and Debt Refinancing Drive Gains

  • Duvakitug Phase 3 Potential Teva's duvakitug, co-developed with Sanofi, is entering Phase 3 trials for ulcerative colitis and Crohn's disease after strong Phase 2b results. Analysts project peak annual sales of $2–5 billion, which could fuel another 50% stock rally. This pipeline success supports future revenue growth and investor optimism.

    This is a new pipeline catalyst that could significantly boost Teva's long-term revenue and stock price.

  • Raised 2026 Revenue Guidance Teva raised its 2026 revenue midpoint by $75 million, driven by strong sales of AUSTEDO, AJOVY, and UZEDY. Combined revenue for these three drugs is now expected at about $3.7 billion. This shows Teva's branded drug strategy is working and boosts confidence in future earnings.

    This is a new guidance raise that directly reflects stronger-than-expected demand for Teva's key products.

  • Direct NYSE Listing and Q2 Sales Beat Teva will replace its ADRs with common stock listed directly on the NYSE starting September 14, which could attract more institutional and retail investors. Q2 sales of $4.1 billion beat estimates, though adjusted EPS missed. The listing change and sales beat drove a 12.3% weekly gain.

    This is a new capital markets event that improves liquidity and investor access, supporting the stock price.

  • $4.9B Debt Refinancing Teva priced $4.9 billion in new senior notes to refinance higher-cost debt, lowering interest expenses. The new notes carry lower coupons than the debt being redeemed, which will improve cash flow and profitability. This strengthens Teva's balance sheet and supports earnings growth.

    This is a new financing action that reduces interest costs and improves financial flexibility, directly benefiting the stock.

▲2

Teva Buys BioXcel Assets, Expands Biosimilar, Accepts Medicaid Price Cuts

  • Teva to acquire BioXcel's IGALMI and BXCL501 assets out of bankruptcy Teva is the stalking horse bidder for BioXcel's assets, including IGALMI and a potential at-home agitation treatment. This adds a commercial drug and a late-stage product to Teva's portfolio, which can boost future revenue. The market initially sent Teva shares down 1%, but the long-term growth potential is positive.

    This is a new acquisition that expands Teva's product portfolio and could drive future revenue.

  • FDA accepts Alvotech's BLA for subcutaneous Entyvio biosimilar, partnered with Teva Alvotech's application for a subcutaneous version of Entyvio, a treatment for ulcerative colitis and Crohn's disease, has been accepted by the FDA. Teva will commercialize it if approved. This advances Teva's biosimilar pipeline, offering a new revenue stream and strengthening its competitive position in immunology.

    This regulatory milestone for a partnered product expands Teva's biosimilar offerings and future sales potential.

  • Teva agrees to Medicaid price cuts and MFN pricing in exchange for tariff relief Teva joined nine other drugmakers in deals to lower Medicaid drug prices to match foreign prices, and to supply 45 tons of metronidazole to the government stockpile. In return, Teva gets relief from import tariffs on pharmaceutical ingredients. The price cuts may pressure revenue, but tariff relief and regulatory clarity are positives.

    This is a major new regulatory and pricing agreement that directly affects Teva's revenue and costs.

Q2 2026
▲4

Teva's branded drug push and biosimilar deals drive growth outlook

  • Ecopipam NDA submitted for pediatric Tourette syndrome Teva filed for FDA approval of ecopipam, a first-in-class Tourette therapy with strong Phase 3 data. If approved, it would be the first new option in over a decade, adding a new branded revenue stream and boosting long-term growth prospects.

    This is a new pipeline catalyst that could drive future sales and shows Teva's innovative focus.

  • Austedo data reinforces growth driver status New clinical data shows Austedo improves symptoms in most tardive dyskinesia and Huntington's chorea patients. As Teva's biggest growth driver, strong data supports continued sales growth, which is key to offsetting generic declines.

    This reinforces the growth story for Teva's top branded drug, directly impacting revenue outlook.

  • European launch of Eylea biosimilar expands market Teva launched Ahzantive, a biosimilar to Eylea, in several European countries. This expands its biosimilar portfolio and adds a new source of revenue in ophthalmology, supporting the company's shift toward higher-margin products.

    New product launch in a major market adds incremental revenue and shows execution of biosimilar strategy.

  • Global licensing deal for Ocrevus biosimilar Teva signed a deal with Polpharma Biologics to commercialize a proposed Ocrevus biosimilar worldwide. This expands Teva's biosimilar pipeline and supports its Pivot to Growth strategy, with Teva handling regulatory and commercialization.

    This strategic deal adds a high-value biosimilar to Teva's pipeline, enhancing long-term growth potential.

June 2026
▲4

Teva's branded drug push and biosimilar deals drive growth outlook

  • Ecopipam NDA submitted for pediatric Tourette syndrome Teva filed for FDA approval of ecopipam, a first-in-class Tourette therapy with strong Phase 3 data. If approved, it would be the first new option in over a decade, adding a new branded revenue stream and boosting long-term growth prospects.

    This is a new pipeline catalyst that could drive future sales and shows Teva's innovative focus.

  • Austedo data reinforces growth driver status New clinical data shows Austedo improves symptoms in most tardive dyskinesia and Huntington's chorea patients. As Teva's biggest growth driver, strong data supports continued sales growth, which is key to offsetting generic declines.

    This reinforces the growth story for Teva's top branded drug, directly impacting revenue outlook.

  • European launch of Eylea biosimilar expands market Teva launched Ahzantive, a biosimilar to Eylea, in several European countries. This expands its biosimilar portfolio and adds a new source of revenue in ophthalmology, supporting the company's shift toward higher-margin products.

    New product launch in a major market adds incremental revenue and shows execution of biosimilar strategy.

  • Global licensing deal for Ocrevus biosimilar Teva signed a deal with Polpharma Biologics to commercialize a proposed Ocrevus biosimilar worldwide. This expands Teva's biosimilar pipeline and supports its Pivot to Growth strategy, with Teva handling regulatory and commercialization.

    This strategic deal adds a high-value biosimilar to Teva's pipeline, enhancing long-term growth potential.

▲4

Teva's branded drug push and biosimilar deals drive growth outlook

  • Ecopipam NDA submitted for pediatric Tourette syndrome Teva filed for FDA approval of ecopipam, a first-in-class Tourette therapy with strong Phase 3 data. If approved, it would be the first new option in over a decade, adding a new branded revenue stream and boosting long-term growth prospects.

    This is a new pipeline catalyst that could drive future sales and shows Teva's innovative focus.

  • Austedo data reinforces growth driver status New clinical data shows Austedo improves symptoms in most tardive dyskinesia and Huntington's chorea patients. As Teva's biggest growth driver, strong data supports continued sales growth, which is key to offsetting generic declines.

    This reinforces the growth story for Teva's top branded drug, directly impacting revenue outlook.

  • European launch of Eylea biosimilar expands market Teva launched Ahzantive, a biosimilar to Eylea, in several European countries. This expands its biosimilar portfolio and adds a new source of revenue in ophthalmology, supporting the company's shift toward higher-margin products.

    New product launch in a major market adds incremental revenue and shows execution of biosimilar strategy.

  • Global licensing deal for Ocrevus biosimilar Teva signed a deal with Polpharma Biologics to commercialize a proposed Ocrevus biosimilar worldwide. This expands Teva's biosimilar pipeline and supports its Pivot to Growth strategy, with Teva handling regulatory and commercialization.

    This strategic deal adds a high-value biosimilar to Teva's pipeline, enhancing long-term growth potential.

Bristol-Myers Squibb Company (BMY)

Q3 2026
▲3▼1

Bristol-Myers Q3: Pipeline Wins, Financial Beat, But Competitive and Legal Risks Loom

  • Strong Q2 results and raised guidance Bristol reported Q2 revenue of about $13 billion and a 40% jump in earnings per share, prompting management to raise full-year revenue guidance to $49–50 billion. Analysts also increased their 2026 EPS estimates to $6.91.

    This shows the company's core financial performance and improved outlook, a key positive driver for the stock.

  • Pipeline and regulatory progress The FDA accepted mezigdomide for review, approved ZENBEXUS for multiple myeloma, and expanded Camzyos to treat pediatric patients. These advances strengthen Bristol's product lineup and help offset future patent losses.

    New drug approvals and expanded uses are direct growth catalysts that can drive future sales and investor confidence.

  • AI and infrastructure investments Bristol partnered with NVIDIA, Schrödinger, and Chai Discovery on AI-driven drug discovery, and opened a new San Diego hub and Houston plant. These investments aim to speed up research and expand manufacturing capacity.

    Long-term growth initiatives that could improve efficiency and innovation, supporting the stock's future potential.

  • Competitive and legal pressures Cytokinetics' Myqorzo threatens Camzyos, J&J's psoriasis pill challenges Sotyktu in China, and AstraZeneca merger talks collapsed. A $6.7B Celgene lawsuit revived, and CAR-T trials paused after Novartis deaths.

    These setbacks create uncertainty and potential revenue loss, weighing on the stock price.

September 2026
▲2▼2

BMY pipeline advances, but competition and safety concerns weigh

  • Pipeline and label expansion Zenbexus won FDA accelerated approval for relapsed multiple myeloma, Camzyos expanded to pediatric patients, and Arlo-cel met its Phase 2 endpoint, strengthening BMY's growth prospects.

    This is a key positive development that could drive future revenue and investor optimism.

  • Analyst EPS estimate raise Growth products now make up 56% of revenue, leading analysts to raise 2026 EPS estimates to $6.91 from $6.34, reflecting confidence in BMY's earnings power.

    This shows improved financial outlook and analyst confidence, which can positively impact the stock.

  • Competitive threat to Sotyktu J&J's oral psoriasis pill won Chinese approval, threatening Sotyktu in a market of over 8 million patients, potentially limiting BMY's growth in a key segment.

    This competitive pressure could hurt BMY's market share and revenue, a negative for the stock.

  • CAR-T trial pause Bristol paused CAR-T trials after Novartis deaths, raising regulatory and safety concerns that could delay development and pressure the stock.

    This introduces uncertainty and potential setbacks in a promising area, negatively impacting investor sentiment.

Latest
▲4

Bristol's Growth Portfolio Accelerates with New Drug Approvals and Strong Pipeline Data

  • Growth Portfolio Now 56% of Revenue, EPS Estimates Raised Bristol's growth products (Opdivo, Camzyos, Sotyktu, etc.) now make up 56% of total revenue, up from 51.8% a year ago, with first-half sales up 13%. Analysts have raised 2026 EPS estimates to $6.91 from $6.34, reflecting confidence that new drugs are replacing older ones losing patent protection. This supports a higher stock price.

    Shows the core shift from legacy to growth products that is driving earnings upgrades and investor optimism.

  • Zenbexus (iberdomide) Wins FDA Approval and Shows Strong Phase 3 Data The FDA granted accelerated approval to Zenbexus for multiple myeloma, the first in a new drug class. In a Phase 3 trial, it doubled the rate of deep responses (MRD-negative complete responses) versus standard treatment. This adds a potential blockbuster revenue stream and validates Bristol's pipeline, lifting the stock.

    A new approved drug with superior efficacy data is a major growth catalyst that directly boosts future revenue expectations.

  • Sotyktu Shows Sustained Two-Year Efficacy in Psoriatic Arthritis Bristol's Sotyktu maintained strong efficacy and safety over two years in patients with psoriatic arthritis, with responses improving through week 104. This supports the drug's long-term use and potential to capture more market share in a large patient population, adding to revenue growth.

    Long-term data reinforces the commercial potential of a key growth product, supporting revenue forecasts.

  • Camzyos Approval Expanded to Pediatric Patients The FDA expanded Camzyos's label to include pediatric patients with obstructive hypertrophic cardiomyopathy, making it the only approved therapy for this age group. This broadens the patient pool and strengthens Camzyos's growth trajectory, a positive for Bristol's revenue outlook.

    Label expansion opens a new patient population, directly increasing the drug's market size and sales potential.

▲3▼2

Bristol's Cancer Pipeline Advances, but Competition and Safety Fears Linger

  • Zenbexus FDA Approval Adds New Myeloma Growth Driver The FDA approved Bristol's oral Zenbexus for relapsed multiple myeloma, a new revenue stream to help replace older drugs losing patent protection. It's an accelerated approval needing confirmatory trials and faces intense competition, so it builds gradually rather than instantly lifting the stock.

    This is a new drug approval that directly adds a future revenue driver for BMY.

  • J&J's Oral Psoriasis Pill Approved in China, Threatening Sotyktu Johnson & Johnson won Chinese approval for its once-daily oral psoriasis pill, which will compete with Bristol's Sotyktu in a market of over 8 million patients. This adds competitive pressure that could limit Sotyktu's growth in China, weighing on BMY's sentiment.

    New competitive threat in a key market that could slow BMY's psoriasis drug sales.

  • Five-Year Camzyos Data Reinforces Long-Term Heart Drug Profile Bristol presented five-year data showing its heart drug Camzyos keeps working safely, with most patients improving. This strengthens confidence in a key growth product and supports its use long-term, a positive for BMY's revenue outlook.

    New clinical data that supports the durability and safety of a key growth drug.

  • CAR-T Safety Concerns After Novartis Deaths; Bristol Pauses Similar Trials Novartis halted CAR-T trials after three patient deaths, and Bristol paused its own similar trials as a precaution. This raises regulatory and safety worries for Bristol's CAR-T programs, adding uncertainty that can pressure the stock until the reviews clear.

    New safety event that directly affects BMY's CAR-T development and investor risk perception.

  • Arlo-cel Meets Primary Endpoint in Phase 2 Myeloma Trial Bristol's experimental CAR-T therapy arlo-cel met its main goal in a mid-stage myeloma trial, showing strong response rates in hard-to-treat patients. This is a potential first-in-class treatment that could become a future growth driver, boosting optimism about the pipeline.

    New positive clinical trial result that advances a potential new therapy for BMY.

August 2026
▲2▼2

BMY beats on earnings, raises guidance, but merger talks collapse

  • Strong Q2 earnings and raised guidance Bristol-Myers Squibb reported Q2 revenue of about $13 billion, beating estimates, with earnings per share jumping 40% to $2.04. Management raised full-year guidance twice, ending at $49–50 billion, driven by Eliquis (+19%) and newer drugs like Camzyos and Reblozyl.

    This is the main positive force behind BMY's stock in August, showing better-than-expected financial performance and improved outlook.

  • FDA approves ZENBEXUS and AI partnerships expand The FDA approved ZENBEXUS for multiple myeloma, adding a new treatment to Bristol's portfolio. The company also expanded AI partnerships with Nvidia, Schrödinger, and Chai Discovery, and announced a $2.3 billion Houston plant, supporting long-term growth.

    These new developments strengthen BMY's pipeline and manufacturing, offering future revenue potential.

  • AstraZeneca merger talks collapse Reported merger talks with AstraZeneca fell apart, removing a potential takeover premium that had lifted BMY's stock. Without a merger, Bristol faces its patent cliff alone, increasing pressure to replace lost revenue from older drugs.

    This is a major negative event that removed a catalyst and leaves BMY more vulnerable to patent expirations.

  • Revived $6.7 billion Celgene lawsuit A $6.7 billion lawsuit related to the Celgene acquisition has been revived, adding legal and financial uncertainty. This could raise BMY's risk premium and pressure the stock as investors weigh potential liabilities.

    This new legal issue introduces uncertainty and potential financial burden, negatively impacting investor sentiment.

▲3▼1

Bristol Raises Outlook, Expands AI and Manufacturing Despite Legal and Competitive Risks

  • Bristol Raises 2026 Revenue Guidance on Eliquis Strength Bristol raised full-year 2026 revenue guidance to $49–$50 billion from $46–$47.5 billion, after Eliquis sales grew 19% to $8.6 billion in the first half. The company now expects Eliquis growth of 20–25% for the year, up from 10–15%, and a smaller decline in older drugs. This directly boosts earnings expectations and investor confidence, pushing BMY shares up.

    This is the most significant new positive catalyst, directly raising revenue and profit outlook.

  • Bristol Partners with Chai Discovery on AI Antibody Discovery Bristol announced a collaboration with Chai Discovery to use AI and machine learning for discovering new therapeutic antibodies. This aims to speed up drug discovery and strengthen the pipeline, supporting long-term growth. While the impact is not immediate, it reinforces Bristol's commitment to innovation and could lead to new revenue streams, positively influencing investor sentiment.

    This new partnership shows Bristol's ongoing investment in AI to enhance pipeline, a key long-term growth driver.

  • Bristol to Invest $2.3 Billion in Houston Manufacturing Plant Bristol announced a $2.3 billion investment in a new Houston manufacturing campus, part of a larger $40 billion U.S. investment pledge. The plant will produce small-molecule medicines, biologics, and antibody-drug conjugates, creating jobs and expanding capacity. This move supports long-term supply chain resilience and may ease tariff pressures, positively affecting BMY's outlook.

    This new capital investment demonstrates commitment to U.S. manufacturing and could mitigate tariff risks, a positive for the stock.

  • Revived $6.7 Billion Celgene Lawsuit Adds Legal Uncertainty A federal appeals court reinstated a $6.7 billion lawsuit alleging Bristol delayed FDA approval of certain drugs to avoid paying contingent value rights to former Celgene shareholders. This brings renewed legal and financial uncertainty, potentially leading to a large cash payout and weighing on investor sentiment. The risk premium on BMY may increase, pressuring the stock price.

    This new legal development introduces a significant potential liability, a negative factor for the stock.

▲3▼1

Bristol's Q2 Beat and New Drug Approval Offset Failed Merger

  • Q2 earnings beat and raised guidance Bristol reported Q2 revenue of $12.97 billion, beating estimates, and raised full-year guidance. Strong sales of Eliquis and newer drugs like Camzyos and Reblozyl drove the beat. This shows the growth portfolio is replacing lost older-drug sales faster than feared, boosting investor confidence and supporting the stock price.

    This is a major positive event that directly impacts BMY's financial outlook and investor confidence.

  • AstraZeneca merger talks called off After reports of merger talks, AstraZeneca's board decided to call them off, and Reuters reported no discussions ever took place. The potential takeover premium evaporated, removing a catalyst that had briefly lifted BMY shares. This leaves BMY to face its patent cliff alone, weighing on sentiment.

    The merger speculation was a key driver of BMY's stock movement, and its termination is a significant negative development.

  • FDA approves ZENBEXUS for multiple myeloma The FDA granted accelerated approval to ZENBEXUS, a first-in-class CELMoD therapy, for relapsed multiple myeloma. This new treatment offers a potential revenue stream to help offset losses from older drugs facing patent expirations, strengthening BMY's oncology portfolio and long-term growth prospects.

    This is a new product approval that directly addresses BMY's need to replace lost revenue from expiring patents.

  • Expanded AI partnerships for drug discovery Bristol expanded its partnership with Nvidia to build a next-generation AI supercomputer and struck a deal with Schrödinger to deploy its AI co-scientist Bunsen. These investments aim to speed up drug discovery and reduce costs, supporting long-term pipeline efficiency and innovation.

    These partnerships highlight BMY's commitment to technological innovation, which could improve future drug development and cost efficiency.

▲2

Bristol Q2 Beat and AstraZeneca Merger Talk Lift BMY

  • Q2 beat and raised full-year guidance Bristol reported roughly $13.0 billion in quarterly revenue, beating expectations by $1.23 billion, with cancer drugs driving growth. Adjusted earnings per share jumped about 40% to $2.04. Management raised full-year revenue and profit guidance above consensus, signaling the growth portfolio is replacing lost older-drug sales faster than feared.

    This is the core fundamental news of the period and directly supports a higher valuation for BMY.

  • Reported AstraZeneca merger talks boost BMY shares The Financial Times and other outlets reported preliminary merger discussions between AstraZeneca and Bristol-Myers Squibb that could create a nearly $400 billion drugmaker. BMY shares rose about 8% in premarket trading before fading to near flat, as investors saw a possible takeover premium but also big antitrust hurdles and doubts a deal gets done.

    This is the single biggest new event moving BMY's stock this period and explains the sharp price reaction.

  • Deal skepticism and antitrust concerns cap the rally AstraZeneca shares fell about 9% while BMY's early 8% gain faded to near flat, showing the market doubts the deal's value and feasibility. Analysts flagged direct competition in lung cancer between Opdivo and Imfinzi, and estimated neither company has the standalone financial firepower to buy the other outright. A deal may never happen.

    It is the essential counterweight to the merger headline and explains why BMY's initial surge did not hold.

July 2026
▲2▼2

Pipeline and AI Advances Offset Pricing and Competition Pressures

  • Cytokinetics launches Myqorzo, competing with Camzyos Cytokinetics launched Myqorzo in the U.S. and Germany for the same heart condition Camzyos treats. With over 275 prescribers already, this new rival could steal Camzyos sales, weighing on BMY's revenue growth.

    This is a new competitive threat that directly pressures a key BMY drug.

  • Trump administration drug-pricing deals include Bristol Myers Squibb Bristol agreed to voluntary most-favored-nation pricing, aligning some U.S. drug prices with lower prices abroad. With top sellers like Revlimid and Eliquis already facing patent expirations, this makes replacing lost revenue even harder.

    This is a new pricing agreement that directly affects BMY's revenue outlook.

  • FDA accepts mezigdomide application for multiple myeloma The FDA accepted Bristol's application for mezigdomide in relapsed multiple myeloma, with a decision expected by May 2027. The drug showed strong trial results, offering a potential new treatment to help offset lost sales from older drugs.

    This is a new regulatory milestone that advances a promising pipeline drug.

  • Bristol expands AI drug discovery with NVIDIA and new San Diego hub Bristol is building the most powerful AI supercomputer in life sciences with NVIDIA and opened a 427,000-square-foot San Diego research hub. These investments aim to speed up drug discovery and improve pipeline efficiency, supporting long-term growth.

    These new technology investments could enhance BMY's ability to develop new drugs faster.

▲2▼2

Pipeline and AI Advances Offset Pricing and Competition Pressures

  • Cytokinetics launches Myqorzo, competing with Camzyos Cytokinetics launched Myqorzo in the U.S. and Germany for the same heart condition Camzyos treats. With over 275 prescribers already, this new rival could steal Camzyos sales, weighing on BMY's revenue growth.

    This is a new competitive threat that directly pressures a key BMY drug.

  • Trump administration drug-pricing deals include Bristol Myers Squibb Bristol agreed to voluntary most-favored-nation pricing, aligning some U.S. drug prices with lower prices abroad. With top sellers like Revlimid and Eliquis already facing patent expirations, this makes replacing lost revenue even harder.

    This is a new pricing agreement that directly affects BMY's revenue outlook.

  • FDA accepts mezigdomide application for multiple myeloma The FDA accepted Bristol's application for mezigdomide in relapsed multiple myeloma, with a decision expected by May 2027. The drug showed strong trial results, offering a potential new treatment to help offset lost sales from older drugs.

    This is a new regulatory milestone that advances a promising pipeline drug.

  • Bristol expands AI drug discovery with NVIDIA and new San Diego hub Bristol is building the most powerful AI supercomputer in life sciences with NVIDIA and opened a 427,000-square-foot San Diego research hub. These investments aim to speed up drug discovery and improve pipeline efficiency, supporting long-term growth.

    These new technology investments could enhance BMY's ability to develop new drugs faster.

Q2 2026
▼3▲1

Pipeline Wins Offset Medicare and China Probe Risks

  • Three pipeline wins in two weeks Bristol reported positive late-stage results for three experimental drugs: SUCCESSOR-2 in multiple myeloma, izalontamab brengitecan in breast and esophageal cancer, and a CAR-T therapy with a 96% response rate. New treatments help replace sales lost as older drugs face cheaper copies.

    This is the main new force lifting BMY: fresh pipeline data that can offset patent losses.

  • Congress probes China trials A House committee opened an investigation into Bristol over clinical trials at Chinese military hospitals and in Xinjiang. This adds legal and reputational risk, and could lead to restrictions or penalties, which weighs on the stock.

    It is a new regulatory threat that could hurt BMY's reputation and operations.

  • Medicare price negotiation risk Proposed changes would make Medicare drug price negotiation permanent from 2029 and tighten rules on fixed-combination drugs. This could pressure future U.S. prices for some Bristol medicines, though legal challenges and a broad product mix may soften the blow.

    It flags a new pricing risk that could lower BMY's future revenue.

  • Roche rival beats Krazati Roche's divarasib outperformed Bristol's Krazati in a Phase III lung cancer trial, meeting survival goals. This competitive threat could erode Krazati's market share and future sales, a negative for BMY.

    It shows a new competitive loss that could reduce BMY's oncology revenue.

June 2026
▼3▲1

Pipeline Wins Offset Medicare and China Probe Risks

  • Three pipeline wins in two weeks Bristol reported positive late-stage results for three experimental drugs: SUCCESSOR-2 in multiple myeloma, izalontamab brengitecan in breast and esophageal cancer, and a CAR-T therapy with a 96% response rate. New treatments help replace sales lost as older drugs face cheaper copies.

    This is the main new force lifting BMY: fresh pipeline data that can offset patent losses.

  • Congress probes China trials A House committee opened an investigation into Bristol over clinical trials at Chinese military hospitals and in Xinjiang. This adds legal and reputational risk, and could lead to restrictions or penalties, which weighs on the stock.

    It is a new regulatory threat that could hurt BMY's reputation and operations.

  • Medicare price negotiation risk Proposed changes would make Medicare drug price negotiation permanent from 2029 and tighten rules on fixed-combination drugs. This could pressure future U.S. prices for some Bristol medicines, though legal challenges and a broad product mix may soften the blow.

    It flags a new pricing risk that could lower BMY's future revenue.

  • Roche rival beats Krazati Roche's divarasib outperformed Bristol's Krazati in a Phase III lung cancer trial, meeting survival goals. This competitive threat could erode Krazati's market share and future sales, a negative for BMY.

    It shows a new competitive loss that could reduce BMY's oncology revenue.

▼3▲1

Pipeline Wins Offset Medicare and China Probe Risks

  • Three pipeline wins in two weeks Bristol reported positive late-stage results for three experimental drugs: SUCCESSOR-2 in multiple myeloma, izalontamab brengitecan in breast and esophageal cancer, and a CAR-T therapy with a 96% response rate. New treatments help replace sales lost as older drugs face cheaper copies.

    This is the main new force lifting BMY: fresh pipeline data that can offset patent losses.

  • Congress probes China trials A House committee opened an investigation into Bristol over clinical trials at Chinese military hospitals and in Xinjiang. This adds legal and reputational risk, and could lead to restrictions or penalties, which weighs on the stock.

    It is a new regulatory threat that could hurt BMY's reputation and operations.

  • Medicare price negotiation risk Proposed changes would make Medicare drug price negotiation permanent from 2029 and tighten rules on fixed-combination drugs. This could pressure future U.S. prices for some Bristol medicines, though legal challenges and a broad product mix may soften the blow.

    It flags a new pricing risk that could lower BMY's future revenue.

  • Roche rival beats Krazati Roche's divarasib outperformed Bristol's Krazati in a Phase III lung cancer trial, meeting survival goals. This competitive threat could erode Krazati's market share and future sales, a negative for BMY.

    It shows a new competitive loss that could reduce BMY's oncology revenue.

© 2026 MarketIVWhy